Switch to:
Also traded in: Germany, Italy, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry
vs
history
Cash to Debt 2.92
NAS:CTIC's Cash to Debt is ranked lower than
66% of the 964 Companies
in the Global Biotechnology industry.

( Industry Median: 46.43 vs. NAS:CTIC: 2.92 )
Ranked among companies with meaningful Cash to Debt only.
NAS:CTIC' s Cash to Debt Range Over the Past 10 Years
Min: 0.01  Med: 1.3 Max: No Debt
Current: 2.92
Equity to Asset 0.23
NAS:CTIC's Equity to Asset is ranked lower than
86% of the 715 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. NAS:CTIC: 0.23 )
Ranked among companies with meaningful Equity to Asset only.
NAS:CTIC' s Equity to Asset Range Over the Past 10 Years
Min: -2.7  Med: 0.05 Max: 0.95
Current: 0.23
-2.7
0.95
F-Score: 5
Z-Score: -41.20
M-Score: -0.31
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) -117.16
NAS:CTIC's Operating margin (%) is ranked lower than
54% of the 749 Companies
in the Global Biotechnology industry.

( Industry Median: -78.20 vs. NAS:CTIC: -117.16 )
Ranked among companies with meaningful Operating margin (%) only.
NAS:CTIC' s Operating margin (%) Range Over the Past 10 Years
Min: -123250  Med: -12650.83 Max: -117.16
Current: -117.16
-123250
-117.16
Net-margin (%) -119.58
NAS:CTIC's Net-margin (%) is ranked lower than
55% of the 749 Companies
in the Global Biotechnology industry.

( Industry Median: -75.28 vs. NAS:CTIC: -119.58 )
Ranked among companies with meaningful Net-margin (%) only.
NAS:CTIC' s Net-margin (%) Range Over the Past 10 Years
Min: -169773.75  Med: -13740.68 Max: -119.58
Current: -119.58
-169773.75
-119.58
ROE (%) -250.54
NAS:CTIC's ROE (%) is ranked lower than
93% of the 878 Companies
in the Global Biotechnology industry.

( Industry Median: -33.45 vs. NAS:CTIC: -250.54 )
Ranked among companies with meaningful ROE (%) only.
NAS:CTIC' s ROE (%) Range Over the Past 10 Years
Min: -1009.15  Med: -275.8 Max: -122.14
Current: -250.54
-1009.15
-122.14
ROA (%) -70.56
NAS:CTIC's ROA (%) is ranked lower than
79% of the 971 Companies
in the Global Biotechnology industry.

( Industry Median: -29.51 vs. NAS:CTIC: -70.56 )
Ranked among companies with meaningful ROA (%) only.
NAS:CTIC' s ROA (%) Range Over the Past 10 Years
Min: -271.76  Med: -122.66 Max: -50.06
Current: -70.56
-271.76
-50.06
ROC (Joel Greenblatt) (%) -1977.49
NAS:CTIC's ROC (Joel Greenblatt) (%) is ranked lower than
70% of the 931 Companies
in the Global Biotechnology industry.

( Industry Median: -372.06 vs. NAS:CTIC: -1977.49 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
NAS:CTIC' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -3033.77  Med: -1866.09 Max: -484.17
Current: -1977.49
-3033.77
-484.17
EBITDA Growth (3Y)(%) -23.90
NAS:CTIC's EBITDA Growth (3Y)(%) is ranked lower than
75% of the 521 Companies
in the Global Biotechnology industry.

( Industry Median: 1.50 vs. NAS:CTIC: -23.90 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
NAS:CTIC' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -83.5  Med: -27.7 Max: 14.5
Current: -23.9
-83.5
14.5
EPS Growth (3Y)(%) -26.60
NAS:CTIC's EPS Growth (3Y)(%) is ranked lower than
76% of the 511 Companies
in the Global Biotechnology industry.

( Industry Median: -4.20 vs. NAS:CTIC: -26.60 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
NAS:CTIC' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -83.3  Med: -26.6 Max: 21.4
Current: -26.6
-83.3
21.4
» NAS:CTIC's 10-Y Financials

Financials (Next Earnings Date: 2017-02-16)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q3 2015

CTIC Guru Trades in Q3 2015

Paul Tudor Jones Sold Out
Jim Simons Sold Out
» More
Q1 2016

CTIC Guru Trades in Q1 2016

Paul Tudor Jones 188,500 sh (New)
Jim Simons 12,200 sh (New)
» More
Q2 2016

CTIC Guru Trades in Q2 2016

Jim Simons 315,544 sh (+2486.43%)
Paul Tudor Jones Sold Out
» More
Q3 2016

CTIC Guru Trades in Q3 2016

Jim Simons 1,966,847 sh (+523.32%)
» More
» Details

Insider Trades

Latest Guru Trades with CTIC

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology
Compare:NAS:KURA, NAS:MDWD, NAS:MRTX, NAS:PRQR, NAS:DMTX, NAS:VBLT, OTCPK:HSDT, OTCPK:INNMF, AMEX:OCX, OTCPK:HBPCF, NAS:VBIV, OTCPK:HPPI, NAS:FATE, NAS:FLKS, NAS:GNCA, NAS:AUPH, NAS:ADVM, OTCPK:SIGA, NAS:CTRV, NAS:PSTI » details
Traded in other countries:CEPR.Germany, CTIC.Italy, 0QUJ.UK,
CTI Biopharma Corp is a biopharmaceutical company. The Company is engaged in acquiring, developing & bringing market less toxic, more effective therapies to treat and cure cancer.

CTI Biopharma Corp was incorporated in Washington in 1991. It is a biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies covering a spectrum of blood-related cancers that offer benefit to patients and health care providers. It is currently concentrating its efforts on treatments that target blood-related cancers where there is an unmet medical need. In particular, it is primarily focused on commercializing PIXUVRI in select countries in the European Union, or the E.U., for multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma, or NHL, and evaluating pacritinib for the treatment of adult patients with myelofibrosis. The Company faces competition from a variety of companies focused on developing oncology drugs. It competes with large pharmaceutical companies and with other specialized biotechnology companies. The Company is subject to extensive regulation by the FDA and other federal, state, and local regulatory agencies.

Ratios

vs
industry
vs
history
P/B 3.81
CTIC's P/B is ranked higher than
52% of the 861 Companies
in the Global Biotechnology industry.

( Industry Median: 3.50 vs. CTIC: 3.81 )
Ranked among companies with meaningful P/B only.
CTIC' s P/B Range Over the Past 10 Years
Min: 0.84  Med: 3.39 Max: 54.81
Current: 3.81
0.84
54.81
P/S 1.02
CTIC's P/S is ranked higher than
94% of the 695 Companies
in the Global Biotechnology industry.

( Industry Median: 10.41 vs. CTIC: 1.02 )
Ranked among companies with meaningful P/S only.
CTIC' s P/S Range Over the Past 10 Years
Min: 0.3  Med: 2.91 Max: 1425
Current: 1.02
0.3
1425
EV-to-EBIT 0.39
CTIC's EV-to-EBIT is ranked higher than
89% of the 252 Companies
in the Global Biotechnology industry.

( Industry Median: 19.98 vs. CTIC: 0.39 )
Ranked among companies with meaningful EV-to-EBIT only.
CTIC' s EV-to-EBIT Range Over the Past 10 Years
Min: -3.7  Med: -0.4 Max: 0.7
Current: 0.39
-3.7
0.7
EV-to-EBITDA 0.40
CTIC's EV-to-EBITDA is ranked higher than
90% of the 276 Companies
in the Global Biotechnology industry.

( Industry Median: 16.24 vs. CTIC: 0.40 )
Ranked among companies with meaningful EV-to-EBITDA only.
CTIC' s EV-to-EBITDA Range Over the Past 10 Years
Min: -5  Med: -0.5 Max: 0.7
Current: 0.4
-5
0.7
Current Ratio 1.47
CTIC's Current Ratio is ranked lower than
81% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 4.22 vs. CTIC: 1.47 )
Ranked among companies with meaningful Current Ratio only.
CTIC' s Current Ratio Range Over the Past 10 Years
Min: 0.38  Med: 2.49 Max: 24.99
Current: 1.47
0.38
24.99
Quick Ratio 1.41
CTIC's Quick Ratio is ranked lower than
78% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 3.94 vs. CTIC: 1.41 )
Ranked among companies with meaningful Quick Ratio only.
CTIC' s Quick Ratio Range Over the Past 10 Years
Min: 0.38  Med: 2.49 Max: 24.96
Current: 1.41
0.38
24.96
Days Inventory 785.18
CTIC's Days Inventory is ranked lower than
98% of the 448 Companies
in the Global Biotechnology industry.

( Industry Median: 128.70 vs. CTIC: 785.18 )
Ranked among companies with meaningful Days Inventory only.
CTIC' s Days Inventory Range Over the Past 10 Years
Min: 15.15  Med: 1080.1 Max: 9023.23
Current: 785.18
15.15
9023.23
Days Sales Outstanding 3.76
CTIC's Days Sales Outstanding is ranked higher than
93% of the 601 Companies
in the Global Biotechnology industry.

( Industry Median: 61.72 vs. CTIC: 3.76 )
Ranked among companies with meaningful Days Sales Outstanding only.
CTIC' s Days Sales Outstanding Range Over the Past 10 Years
Min: 2.47  Med: 21.79 Max: 834.94
Current: 3.76
2.47
834.94
Days Payable 3.00
CTIC's Days Payable is ranked lower than
92% of the 412 Companies
in the Global Biotechnology industry.

( Industry Median: 57.94 vs. CTIC: 3.00 )
Ranked among companies with meaningful Days Payable only.
CTIC' s Days Payable Range Over the Past 10 Years
Min: 3  Med: 2592.11 Max: 49126.02
Current: 3
3
49126.02

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -36.70
CTIC's 3-Year Average Share Buyback Ratio is ranked lower than
81% of the 555 Companies
in the Global Biotechnology industry.

( Industry Median: -11.30 vs. CTIC: -36.70 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
CTIC' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -442.4  Med: -63.4 Max: 5.3
Current: -36.7
-442.4
5.3

Valuation & Return

vs
industry
vs
history
Price/Net Cash 18.33
CTIC's Price/Net Cash is ranked lower than
79% of the 518 Companies
in the Global Biotechnology industry.

( Industry Median: 6.05 vs. CTIC: 18.33 )
Ranked among companies with meaningful Price/Net Cash only.
CTIC' s Price/Net Cash Range Over the Past 10 Years
Min: 1.46  Med: 2.38 Max: 19
Current: 18.33
1.46
19
Price/Net Current Asset Value 6.88
CTIC's Price/Net Current Asset Value is ranked lower than
56% of the 630 Companies
in the Global Biotechnology industry.

( Industry Median: 5.53 vs. CTIC: 6.88 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
CTIC' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 1.19  Med: 3.96 Max: 95
Current: 6.88
1.19
95
Price/Tangible Book 3.67
CTIC's Price/Tangible Book is ranked higher than
60% of the 785 Companies
in the Global Biotechnology industry.

( Industry Median: 4.33 vs. CTIC: 3.67 )
Ranked among companies with meaningful Price/Tangible Book only.
CTIC' s Price/Tangible Book Range Over the Past 10 Years
Min: 0.79  Med: 2.09 Max: 82.61
Current: 3.67
0.79
82.61
Price/Median PS Value 0.35
CTIC's Price/Median PS Value is ranked higher than
89% of the 589 Companies
in the Global Biotechnology industry.

( Industry Median: 0.93 vs. CTIC: 0.35 )
Ranked among companies with meaningful Price/Median PS Value only.
CTIC' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.1  Med: 0.42 Max: 570
Current: 0.35
0.1
570
Earnings Yield (Greenblatt) (%) 257.03
CTIC's Earnings Yield (Greenblatt) (%) is ranked higher than
97% of the 942 Companies
in the Global Biotechnology industry.

( Industry Median: -8.50 vs. CTIC: 257.03 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
CTIC' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 144.6  Med: 478.35 Max: 2146.8
Current: 257.03
144.6
2146.8

More Statistics

Revenue (TTM) (Mil) $59.59
EPS (TTM) $ -0.27
Beta-0.04
Short Percentage of Float0.16%
52-Week Range $0.25 - 1.34
Shares Outstanding (Mil)282.30

Analyst Estimate

Dec16
Revenue (Mil $)
EPS ($) -0.78
EPS w/o NRI ($) -0.78
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
Dividends Per Share ($)
» More Articles for NAS:CTIC

Headlines

Articles On GuruFocus.com
Monday Morning Pre-Market Insights: Celldex Therapeutics, Celladon Corp, CTI BioPharma Corp, TG Ther Jun 01 2015 
Weekly CEO Sells Highlight: Groupon Inc., Cell Therapeutics Inc., Standard Pacific Corp and Dollar G Mar 24 2014 
These 4 Biotech Stocks Are a Buy Now Feb 08 2012 
Cell Therapeutics Inc. (CTIC) CEO James A Bianco sells 50,000 Shares Feb 25 2011 
Cell Therapeutics Inc. (CTIC) CEO James A Bianco sells 50,000 Shares Jan 28 2011 
Weekly CEO Sells Highlight: CTIC, DDR, UNM, BRCM, TC Jan 09 2011 
Cell Therapeutics Inc. (CTIC) CEO James A Bianco sells 250,000 Shares Jan 03 2011 
Cell Therapeutics Inc. (CTIC) CEO James A Bianco sells 200,000 Shares Dec 17 2010 
Cell Therapeutics Inc. (CTIC) CEO James A Bianco sells 150,000 Shares Dec 10 2010 
Cell Therapeutics Inc. (CTIC) CEO James A Bianco sells 100,000 Shares Nov 05 2010 

More From Other Websites
10:36 am CTI BioPharma announces the PERSIST-2 Phase 3 study of pacritinib vs best available therapy... Dec 06 2016
PERSIST-2 Phase 3 Study Of Pacritinib Versus Best Available Therapy Shows Encouraging Clinical... Dec 06 2016
ETFs with exposure to CTI BioPharma Corp. : December 2, 2016 Dec 02 2016
CTI BioPharma Presents Nonclinical Pharmacology Study Demonstrating Pacritinib Has Distinct Profile... Dec 01 2016
CTI BIOPHARMA CORP Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD... Nov 30 2016
CTI BIOPHARMA CORP Financials Nov 30 2016
CTI BioPharma Announces Phase 3 Data from the PERSIST-2 Trial of Pacritinib to be Presented in... Nov 21 2016
BrainStorm Cell Therapeutics Reports Third Quarter 2016 Financial Results Nov 15 2016
ETF’s with exposure to CTI BioPharma Corp. : November 10, 2016 Nov 10 2016
CTI BioPharma Corp. :CTIC-US: Earnings Analysis: Q3, 2016 By the Numbers : November 9, 2016 Nov 09 2016
CTI BIOPHARMA CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Nov 08 2016
CTI BioPharma reports 3Q loss Nov 08 2016
CTI BioPharma reports 3Q loss Nov 08 2016
CTI BioPharma Reports Third Quarter 2016 Financial Results Nov 08 2016
CTI BIOPHARMA CORP Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD... Oct 31 2016
CTI BIOPHARMA CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Termination of a... Oct 24 2016
5 Biotech Penny Stocks Smart Money Is Piling On Oct 23 2016
CTI BIOPHARMA CORP Files SEC form 8-K, Change in Directors or Principal Officers, Financial... Oct 03 2016
CTI BioPharma Announces Retirement Of President And CEO Oct 03 2016
CTI BIOPHARMA CORP Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD... Sep 29 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)